Ibogaine Drug Interactions & QTc: Educational Screening Literacy

Definition box

Definition: Ibogaine drug interactions are medication, supplement, and substance combinations that may increase toxicity—especially QTc prolongation / arrhythmia risk—or alter ibogaine/noribogaine exposure via pathways such as CYP2D6. In physician-supervised IV ibogaine infusion (psychoactive intravenous ibogaine), interaction review sits inside consult → ECG/labs → continuous monitoring → integration. Evidence gap: Most published human interaction/safety signals come from oral contexts (Knuijver QTc open-label; Glue CYP2D6 PK work; Obach metabolism). Cherian/MISTIC = oral ibogaine + IV magnesium support—not a complete IV-interaction label. This page is educational literacy, not a personal stop/start list and not a complete interaction database. Ibogaine is U.S. Schedule I / not FDA-approved. Provisional Mexico programs ≠ FDA/US clinics. No DIY dosing. No cure claims.

Quotable answer (55 words)

Ibogaine drug interactions center on QTc-prolonging medications, electrolyte threats, and CYP2D6 inhibitors that can raise exposure. IV ibogaine infusion still requires physician supervision and cardiac monitoring; most published human data reflect oral dosing. Unsupervised polypharmacy with ibogaine is dangerous. Not FDA-approved. Not medical advice.

How to use this page (and how not to)

Do: bring a full med/supplement list to a licensed clinician; ask about QT risk and metabolism. Don’t: use this article as permission to stop prescriptions, stack “detox herbs,” or dose ibogaine at home.

Safety: /safety-and-screening · CYP2D6 deep dive: /blog/ibogaine-cyp2d6-metabolism · Contraindications: /blog/ibogaine-contraindications · Side effects: /blog/ibogaine-side-effects.

Mechanism buckets clinicians care about

1) Additive QTc / arrhythmia risk Ibogaine (and related clinical conversation around parent/metabolite effects) is associated with **QTc prolongation**. Combining with other QT-prolonging drugs can reduce repolarization reserve.

Educational theme examples clinicians often review (non-exhaustive, not a ban list you should self-apply):

• Certain antipsychotics
• Certain antibiotics (classic teaching includes some macrolides/fluoroquinolones)
• Certain antiarrhythmics
• Some antiemetics
• Methadone in some risk profiles
• Other miscellaneous QT-prolonging agents per current clinical references

Exact decisions are clinician-owned and indication-dependent.

2) Electrolyte and physiologic amplifiers Low potassium or magnesium, bradycardia, structural heart disease, congenital long QT, female sex as a population QT-risk factor in broader TdP teaching, and recent stimulant strain can amplify risk. Stimulant and cocaine context: /blog/ibogaine-for-cocaine-stimulants.

3) CYP2D6-mediated exposure changes Ibogaine O-demethylation to noribogaine is catalyzed primarily by **CYP2D6** (Obach et al.). Glue et al. showed CYP2D6 inhibition (paroxetine pretreatment) markedly altered oral ibogaine PK and increased active-moiety exposure in healthy volunteers. Later OUD PK/PD work links CYP2D6 activity score to clearance and relates concentrations to QTc.

CYP2D6 inhibitor examples often discussed in pharmacology teaching (educational themes only): some SSRIs (e.g., paroxetine, fluoxetine), some other inhibitors—your clinician maps your list.

4) CNS depressant / withdrawal complexity Benzodiazepines, alcohol, opioids, and other sedatives create separate withdrawal and monitoring problems (/blog/ibogaine-and-benzodiazepines · /blog/ibogaine-for-fentanyl).

Oral literature anchors (route-labeled)

| Citation | Route / design | Teaching use | |----------|----------------|--------------| | Knuijver et al., *Addiction* 2021 | Oral HCl, open-label OUD | QTc prolongation clinically relevant in small series | | Glue et al., *J Clin Pharmacol* | Oral 20 mg + CYP2D6 inhibition | Exposure rises when CYP2D6 impaired | | Obach et al. | In vitro / metabolism | CYP2D6 primary O-demethylation | | Cherian et al., *Nat Med* 2024 | Oral + IV Mg | Support Mg ≠ psychoactive IV proof |

Brunt and related cardiovascular reviews continue to emphasize rare-but-relevant QT/arrhythmia complications in the broader ibogaine conversation—still not a license to invent IV RCT interaction tables.

Support IV vs psychoactive IV (interaction confusion)

Marketing sometimes says “we give IV magnesium, so interactions don’t matter.” False.

• IV magnesium / fluids / antiemetics = support, when used
• Psychoactive IV ibogaine = the entity on this site
• Support measures do not erase medication reconciliation

MISTIC used oral ibogaine + IV magnesium—label that every time (/blog/stanford-ibogaine-mistic · /blog/electrolytes-support-iv-vs-psychoactive-iv · /blog/ibogaine-oral-vs-iv).

Practical screening questions to ask a program

1. Who reviews my full medication list for QT and CYP interactions?
2. Will I have a pre-infusion ECG and electrolyte labs?
3. What is the continuous monitoring plan during psychoactive dosing?
4. How do you handle methadone, SSRIs, antipsychotics, or antibiotics if present?
5. Do you genotype CYP2D6 or otherwise individualize risk discussion? (Neither is a cure; both are literacy topics.)
6. Is psychoactive route written as IV or oral?
7. Emergency defibrillation/transfer plan?

Vetting: /blog/how-to-choose-an-ibogaine-clinic · Red flags: /blog/cheap-ibogaine-clinic-red-flags · Consent: /blog/ibogaine-informed-consent-questions.

What this page will not do

• Provide a printable “safe meds with ibogaine” whitelist
• Tell you to stop antidepressants or heart meds
• Give DIY timing charts
• Quote fake interaction percentages for IV psychoactive dosing

Legal / geography

Ibogaine remains U.S. Schedule I and not FDA-approved (/blog/is-ibogaine-legal-us). Provisional Mexico programs discussed on this site are not FDA/US clinics (/blog/ibogaine-mexico-medical-vs-tourism). Travel does not shrink interaction risk.

Polypharmacy patterns common in applicants

Real screening packets often include antidepressants, antipsychotics, sleep aids, antiemetics from prior detox attempts, HIV or hepatitis therapies, hormone therapies, and over-the-counter antihistamines. Each item deserves a clinician’s eye for QT, sedation, and metabolic overlap—not a blog whitelist.

Opioid agonist contexts (methadone/buprenorphine literacy): /blog/ibogaine-vs-methadone · /blog/ibogaine-vs-suboxone. Alcohol-interest readers: /blog/ibogaine-for-alcohol-use-disorder.

After an interaction-heavy “near miss”

If a program brushed off your medication list, document what was said, seek independent clinical advice, and reconsider participation. Cheap speed is not a cardiac strategy (/blog/cheap-ibogaine-clinic-red-flags). Aftercare still matters if a supervised session proceeds (/blog/ibogaine-aftercare-integration).

Soft CTA

Bring interactions to the medical front—not the deposit front. Read /safety-and-screening, then request a confidential screening consult via /apply. FAQ: /faq · Entity: /what-is-ibogaine-infusion.

FAQ

What are the most important ibogaine drug interactions? Clinically, focus on QT-prolonging drugs, electrolyte threats, CYP2D6 inhibitors affecting exposure, and complex sedative/opioid/benzo situations—reviewed by clinicians.

Does IV infusion remove interaction risk? No. Psychoactive IV still needs monitoring and med review.

Is most interaction/safety evidence oral? Yes. Controlled psychoactive-IV evidence is sparse.

Did MISTIC prove IV interactions are solved with magnesium? No. MISTIC used **oral** ibogaine + **IV magnesium** support.

Should I stop my SSRI before ibogaine because of CYP2D6? Do not stop psychiatric medicines based on blogs. Ask the prescribing clinician and the screening team.

Can supplements interact? Yes—full lists matter (including “natural” products). Clinician review only.

Is ibogaine FDA-approved so interactions are on a label? No. Not FDA-approved; no consumer package-insert playbook for this use.

Where should I go next? /safety-and-screening then /apply.

Medical disclaimer

Educational interaction literacy only—not a complete interaction checker, medical advice, or legal advice. Do not self-administer ibogaine. Do not change prescribed medicines without licensed clinicians. Cardiac events can be life-threatening.

Sources (selected)

1. Knuijver T. et al. *Addiction*. 2021 — oral ibogaine HCl; QTc findings.
2. Glue P. et al. *Journal of Clinical Pharmacology* — CYP2D6 activity influences ibogaine/noribogaine PK.
3. Obach R.S. et al. — CYP2D6 catalyzes ibogaine O-demethylation.
4. Cherian K.N. et al. *Nature Medicine*. 2024 — oral ibogaine + IV magnesium (MISTIC).
5. Mosca A. et al. *Current Neuropharmacology* — limited RCTs; cardiotoxicity concerns.
6. 21 CFR 1308.11 — Schedule I (ibogaine).